Filing Overview
This Form 8-K was filed by Blue Water Vaccines Inc., not Onconetix, Inc., and reports events occurring on November 4, 2022. The filing date was November 8, 2022. The company is incorporated in Delaware and its common stock traded on Nasdaq under the symbol BWV.
Business and Governance Changes
- Michael Venerable resigned from the company’s Board of Directors effective November 4, 2022.
- The filing states that his resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices.
- Vuk Jeremić was appointed to the Board effective November 4, 2022.
- Mr. Jeremić was also appointed to the Nominating and Corporate Governance Committee and the Compensation Committee.
- The company described Mr. Jeremić’s background in international relations, public policy, strategy, and advisory roles as relevant to his appointment.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics. It is a governance and Regulation FD filing rather than a financial-results report.
Material Changes, Outlook, and Risks
No financial guidance, operating outlook, material contracts, contingencies, or new business risks are disclosed in the provided filing text. The company states that no family relationships exist between Mr. Jeremić and its directors or executive officers and that no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K was identified.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for Blue Water Vaccines Inc., while the request metadata identifies Onconetix, Inc.
- Confirm the effective date and scope of Michael Venerable’s resignation.
- Review the company’s current Board and committee composition following Mr. Jeremić’s appointment.
- Review Exhibit 99.1, the November 8, 2022 press release, for any additional commentary.
- Use separate periodic filings to assess financial condition, liquidity, capital requirements, and operating performance.